"In the mouse model, we were able to show that the signal for the disease can be directed from the outside to the inside, and not just vice versa," explains study leader Erwin Wagner, who recently brought his international group from the Spanish Cancer Research Centre (CNIO) to Med Uni Vienna. The pivotal result of the study, which has now appeared in the top journal EMBO Molecular Medicine, is that genetic changes in the hair follicles of epidermal stem cells can lead to deregulated expression of transcription factors, such as the Activator Protein-1 (AP-1) proteins, which can cause inflammatory reactions and thus trigger psoriasis via the immune system. Says Wagner: "If you switch off the target genes of the transcription factors, the inflammation is slowed down significantly."
"This basic research finding is an important step towards a better understanding of this heterogeneous disease," adds Latifa Bakiri from the study group at the Clinical Institute for Laboratory Medicine.
Possible therapeutic target identified
The researchers were also able to show that the immune mediator TSLP (Thymic Stromal Lymphopoietin), which is high in psoriasis, plays a significant role in this process. "If you inhibit TSLP, the disease is almost stopped. This makes TSLP a potential target for therapeutic use in humans as well in the future", says Wagner,but this requires further research.
The great importance of AP-1 proteins in skin inflammation is also underscored by a second study from this international group of scientists. In the recently published paper in Cell Reports, it was shown that AP-1 proteins are also important in Atopic Dermatitis (AD), another common inflammatory skin disease (often called eczema), where these proteins control the colonization of bacteria such as Staphylococcus aureus in the skin, a frequent health problem for AD patients.
Service: EMBO & Cell Reports
"Role of bulge epidermal stem cells and TSLP signaling in psoriasis." N. Gago-Lopez, LF. Mellor, D. Megias, G. Martin Serrano, A. Izeta, F. Jimenez, E. Wagner. EMBO Mol Med. 2019 Nov 7; 11 (11): e10697. DOI: 10.15252 / emmm.201910697.
"Cutaneous Immune Cell-Microbiota Interactions Are Controlled by Epidermal JunB / AP-1." Uluckan, M. Jimenez, B. Roediger, J. Schnabl, L. Diez-Corodova, K. Troulé, W. Weninger, E. Wagner. Cell Rep. 2019 Oct 22; 29 (4): 844-859.e3. doi: 10.1016 / j.celrep.2019.09.042.